Terray Therapeutics Secures $120M Series B Funding to Advance AI-Driven Small Molecule Drug Development

Funding:
Terray Therapeutics has raised $120 million in a Series B funding round to further develop its AI-powered small molecule drug discovery platform.

Purpose:
The funding will be used to advance AI-powered small molecules into clinical trials and expand research and development into autoimmune diseases.

Platform:
Terray's platform integrates chemical experimentation and computation at scale, generating vast amounts of precise data to train AI systems for rapid drug discovery.

Innovation:
The company's AI-driven approach allows for the digital design of drug molecules, which are then synthesized and tested in high-speed automated laboratories, creating a powerful feedback loop for continuous improvement.

Impact:
This innovative approach aims to solve complex problems in drug discovery more efficiently and effectively than traditional methods, potentially leading to faster development of new treatments.